id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-258873-l9oxmqdp	Baker, D.	COVID‐19 vaccine‐readiness for anti‐CD20‐depleting therapy in autoimmune diseases	2020-08-01		.txt	text/plain	6017	323	44	It appears that the innate immune response, and perhaps later anti-viral CD8 T cell responses, could eliminate the SARS-CoV2 before significant antibody responses have developed [20, 28, 33] (Fig. 1) , suggesting that most MS treatments that largely exhibit limited persistent effects on the innate immune and CD8 T cell responses would have limited influence on COVID-19. The suggestion that rituximab treatment may increase risk of infection should be considered in the context of possible sampling biases, although this Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infects cells in the lung and the gut via the angiotensin-converting enzyme 2 (ACE2). If COVID-19-related vaccine responses become a key concern among people with MS or other autoimmune diseases choosing treatment options, the selection of B cell-depleting agents that allow quick repopulation of B cells may be relevant for optimum vaccine readiness.	./cache/cord-258873-l9oxmqdp.txt	./txt/cord-258873-l9oxmqdp.txt